Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
Alnylam has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. 16 July 2025
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), extending its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. 4 August 2025
Biotechnology
Philadelphia, USA-based Medicus Pharma and Boston-based biotech Helix Nanotechnologies have entered into a non-binding memorandum of understanding (MoU) in respect of their shared mutual interest in the development of thermostable infectious diseases vaccines. 4 August 2025
Biotechnology
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate slowing of decline, with most participants having completed treatment, US pharma major Eli Lilly announced today. 4 August 2025
Pharmaceutical
Chinese biotech TenNor Therapeutics has filed to list on the main board of the Hong Kong Stock Exchange, aiming to fund late-stage development and commercialization of its pipeline of new antibacterial treatments. The Suzhou-based company is seeking to go public under Chapter 18A, a pathway for pre-revenue drugmakers. 4 August 2025
Pharmaceutical
Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s CSPC Pharma for rights to a GLP-1 receptor inhibitor, SYH 2086, to compliment its platform in metabolic dysfunction associated steatohepatitis (MASH) – led by Rezdiffra. US President Donald Trump issued an ultimatum to a number of major pharmaceutical companies demanding that they reduce the price of their drugs in the USA. Also of note, LENZ Therapeutics received US Food and Drug Administration (FDA) approval for its VIZZ, the first aceclidine-based drug for the treatment of presbyopia in adults. 3 August 2025
Pharmaceutical
The US Food and Drug Administration (FDA) approved San Diego, USA-based LENZ Therapeutics’ VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. 2 August 2025
Biotechnology
Swiss pharma giant Roche announced positive five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo (ranibizumab injection) for the treatment of people with neovascular or ‘wet’ age-related macular degeneration (nAMD). 2 August 2025
Pharmaceutical
US RNA interference (RNAi) specialist Arrowhead Pharmaceuticals today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France’s Sanofi to develop and commercialize four of Arrowhead’s investigational cardiometabolic candidates in Greater China. 2 August 2025
Biotechnology
US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent. 1 August 2025
Biotechnology
US Biotech Regeneron Pharmaceuticals today announced financial results for the second quarter of 2025 and provided a business update.
Revenue grew by 4% year-over-year to $3.68 billion, outpacing forecasts of $3.30 billion. 1 August 2025
Latest In Brief for Alnylam Pharmaceuticals
Pharmaceutical
US pharma major AbbVie is considering a $1-billion acquisition of Gilgamesh Pharmaceuticals, Bloomberg News reported on Wednesday, citing people familiar with the matter. 31 July 2025
Latest Relevant Ones To Watch News
Chinese biotech TenNor Therapeutics has filed to list on the main board of the Hong Kong Stock Exchange, aiming to fund late-stage development and commercialization of its pipeline of new antibacterial treatments. The Suzhou-based company is seeking to go public under Chapter 18A, a pathway for pre-revenue drugmakers. 4 August 2025
17 June 2025
16 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze